Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 3/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.31 |
| ▸ | BTK | Q06187 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16110183 | 0.85 | AR (0.39) | ARESR2LPLLIPGJAK2 | |
| SCHEMBL17698755 | 0.85 | JAK2 (0.39) | ESR2LPLLIPGJAK2BTK | |
| SCHEMBL12703333 | 0.83 | LPL (0.42) | LPLLIPGJAK2BTK | |
| SCHEMBL16109829 | 0.83 | IMPDH2 (0.31) | ARESR2 | |
| SCHEMBL21592307 | 0.79 | LPL (0.39) | ARESR2LPLLIPG | |
| SCHEMBL23631403 | 0.78 | ESR2 (0.33) | ESR2LPLLIPGJAK2BTK | |
| SCHEMBL1495731 | 0.78 | ESR2 (0.33) | ARESR2LPLLIPG | |
| SCHEMBL30905966 | 0.78 | ESR2 (0.33) | ARESR2LPLLIPG | |
| SCHEMBL18230306 | 0.78 | AR (0.34) | ARESR2LPLLIPG | |
| SCHEMBL9988818 | 0.77 | IMPDH2 (0.44) | ARLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3336084-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-9944626-B2 | 6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-2978752-B1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-11-29 | — | — | EP | disclosed |
| US-20170275271-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9708296-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20160251337-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9345713-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| EP-2978752-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-08-13 | — | — | US | disclosed |
| US-9040522-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140296200-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014160810-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | SIRT1, SIRT3, SIRT5 | AR 4031/4885ESR2 4558/4885LPL 3594/4885 |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | AR 2897/4885ESR2 1533/4885LPL 4453/4885 |
| US-20170275271-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | AR 2897/4885ESR2 1533/4885LPL 4453/4885 |
| US-20140296200-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | AR 2897/4885ESR2 1533/4885LPL 4453/4885 |
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | HIF1AN, EGLN3, EGLN2 | AR 2897/4885ESR2 1533/4885LPL 4453/4885 |
| US-20160251337-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | AR 2897/4885ESR2 1533/4885LPL 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.